Vax-Plasma in Patients With Refractory COVID-19
- 12 November 2021
- journal article
- letter
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 97 (1), 186-189
- https://doi.org/10.1016/j.mayocp.2021.11.001
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infectionScience, 2021
- Use of convalescent plasma inCOVID‐19 patients with immunosuppressionTransfusion, 2021
- Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritisClinical and Experimental Rheumatology, 2021
- The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysisMayo Clinic Proceedings, 2021
- Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritisRheumatology, 2021
- Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19Blood, 2020
- OP0338 MASS SPECTROMETRY IDENTIFIES NOVEL BIOMARKERS IN GIANT CELL ARTERITIS, USEFUL IN PATIENTS ON INTERLEUKIN-6 RECEPTOR BLOCKADEAnnals Of The Rheumatic Diseases, 2020
- Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literatureBritish Journal of Haematology, 2020
- Trial of Tocilizumab in Giant-Cell ArteritisThe New England Journal of Medicine, 2017
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014